Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer.

Jiahong Tan,Daoqi Wang,Qinglei Gao,Yigang Hu,Chunyan Song,Dan Liu,Ding Ma

doi:10.1042/bsr20210478

Jiahong Tan, Daoqi Wang + Show 5 more

Open Access

https://doi.org/10.1042/bsr20210478

Copy DOI

Journal: Bioscience reports	Publication Date: May 6, 2021
Citations: 10	License type: CC BY 4.0

Affiliation: Tongji Hospital, Wuhan Union Hospital

Abstract

High-grade serous ovarian cancer (HGSOC) has abundant expression of hormone receptors, including androgen receptor (AR), estrogen receptor α (ER), and progesterone receptor (PR). The effects of hormone receptors on prognosis of HGSOC were first evaluated in online databases. Their prognostic values were then explored and validated in our inhouse TJ-cohort (92 HGSOC patients) and in a validation cohort (33 HGSOC patients), wherein hormone receptors were detected immunohistochemically. High expression of hormone receptors denoted longer progression-free survival (PFS), overall survival (OS), and platinum-free interval (PFI). Platinum-sensitive patients had higher expression of hormone receptors than their counterparts. Correlation analysis revealed significant positive correlations between hormone receptors expression and survival. AR, ER, and PR had predictive and prognostic values, alone and in combination. By receiver operating characteristic curve (ROC) analysis, co-expression of AR, ER, and PR had an improved predictive performance with an area under the curve (AUC) value of 0.945. Expression of hormone receptors predicts survival and platinum sensitivity of HGSOC. AR, ER, and PR might be feasible prognostic biomarkers for HGSOC by immunohistochemical analysis.

Highlights

Ovarian cancer is the second leading cause of gynecologic cancer deaths in women around the world, with 152000 deaths annually [1]
We found that the expression of androgen receptor (AR), estrogen receptor α (ER), and progesterone receptor (PR) predicted survival and platinum sensitivity of ovarian cancer
The prognostic values of hormone receptors were confirmed in our in-house High-grade serous ovarian cancer (HGSOC) cohorts, wherein their expression was detected immunohistochemically

Summary

Introduction

Ovarian cancer is the second leading cause of gynecologic cancer deaths in women around the world, with 152000 deaths annually [1]. The 5-year survival rate of ovarian cancer remains unchanged at approx. High-grade serous ovarian cancer (HGSOC) is the most common histological subtype and has aggressive tumor biology [1,2]. Platinum-based chemotherapy has been the standard of care for HGSOC for almost 40 years [3]. Most HGSOC patients will receive platinum-containing regimens as the first-line treatment option [1,4]. Without pre-determination of platinum responsiveness, 30% of patients have undergone multiple rounds of useless and even toxic treatment [5]. As a highly deadly and heterogeneous disease, subtype-specific biomarkers for the large group of HGSOC patients are urgently needed [6]

Methods

Results

Conclusion